Katsuji Hironaka

Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432.

Katsuji Hironaka, Yoshiyuki Yamaguchi, Riki Okita et al. · PubMed · 2006 · 23 citations

Life Sciences, Immunology, Oncology +15

Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: Possible application for compensatory anti-inflammatory response syndrome

Yoshiyuki Yamaguchi, Jun Hihara, Katsuji Hironaka et al. · Oncology Reports · 2006 · 21 citations · Full text

Medicine, Immunology, Oncology +15

Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.

Yoshiyuki Yamaguchi, Koji Ohta, Yoshiharu Kawabuchi et al. · PubMed · 2005 · 19 citations

Medicine, Immunology, Oncology +16

HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.

Yoshiyuki Yamaguchi, Katsuji Hironaka, Makoto Okawaki et al. · PubMed · 2005 · 15 citations

Medicine, Immunology, Oncology +11

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

Mitsugu Kochi, Yuji Akiyama, Tatsuya Aoki et al. · Cancer Chemotherapy and Pharmacology · 2013 · 10 citations

Medicine, Oncology, Pharmacology +10